Clinical Trial

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.
Trial Details
NCT Number NCT07382687
Lead Sponsor Fudan University
Conditions Breast Cancer
Enrollment 248 participants
Start Date 2026-02-26
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-03